GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024 17:00 ET
|
GT Biopharma, Inc.
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...